- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Highlights**: For the quarter, revenue from operations decreased by 4.69% quarter-on-quarter (Q-o-Q) to ₹89.10 Cr, reflecting a slight increase of 1.30% year-on-year (Y-o-Y). The total income dropped by 9.77% to ₹88.97 Cr compared to the previous quarter, with a year-to-date total of ₹249.39 Cr. Operating expenses increased by 2.53% Q-o-Q, impacting EBITDA, which fell to ₹5.10 Cr, resulting in an EBITDA margin decline to 5.72%. Profit after tax also saw a stark drop, declining by 86.99% to ₹1.28 Cr.
**Strategic Initiatives and Growth Drivers**: Despite current challenges in demand due to lower disease outbreaks impacting exports, the company remains on track with capital expenditure plans. The completion of Phase 1 of the CAPEX project is expected soon, which is crucial for expanding market presence in the US and EU.
**Business Developments**: The company highlighted ongoing efforts in capacity expansion to meet increasing demand, with significant investments planned for their operations.
**Market Position and Competitive Advantage**: NGL Fine-Chem holds a strong position in the veterinary API segment with a well-diversified product portfolio aimed at various global markets. Leadership in key products ensures stability amidst fluctuating market conditions.
**Investor Implications**: While the immediate outlook reflects operational challenges, the strategic investments and market leadership position create a foundation for potential growth as market conditions normalize.